RVNC Revance Therapeutics Inc.

28.13
+0.38  (+1%)
Previous Close 27.75
Open 27.82
52 Week Low 14.2
52 Week High 34.62
Market Cap $2,008,000,808
Shares 71,382,894
Float 68,606,884
Enterprise Value $1,756,479,308
Volume 317,252
Av. Daily Volume 480,993
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
DAXI (RT002)
Moderate to severe glabellar (frown) lines
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
DAXI (RT002) - ASPEN-1/ASPEN-OLS
Cervical dystonia
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
DAXI (RT002) - JUNIPER
Upper limb spasticity
Phase 2
Phase 2
Phase 2 top-line data released February 22, 2021. One of two co-primary endpoints met (one missed due to reduced enrollment).
DAXI (RT002)
Upper facial lines
Phase 2
Phase 2
Phase 2 data released December 17, 2020 - efficacy of none or mild wrinkle severity seen in greater than 92% of subjects after four weeks.
DAXI (RT002)
Plantar fasciitis
Phase 2
Phase 2
Phase 2 data did not meet primary endpoint - November 9, 2020.
DAXI (RT002)
Forehead lines
Phase 2
Phase 2
Phase 2 data noted 100% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group - June 30, 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 2
Phase 2
Phase 2 top-line data released June 30, 2020. 88% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group.

Latest News

  1. Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 12-15.

    President and Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, April 13, at 7:15 a.m. PT / 10:15 a.m. ET.

    Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

    About Revance Therapeutics,

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 12-15.

    President and Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, April 13, at 7:15 a.m. PT / 10:15 a.m. ET.

    Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

    About Revance Therapeutics, Inc.

    Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

    "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

    Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

    BOTOX® is a registered trademark of Allergan, Inc.

    View Full Article Hide Full Article
  2. Revance Therapeutics (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021. Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

    "We're pleased to present the efficacy and safety findings from the ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection at this year's 2021 AAN Virtual Meeting, specifically, the median duration of effect of up to 24 weeks, as determined by time to loss of…

    Revance Therapeutics (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ePoster at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting taking place from April 17-22, 2021. Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

    "We're pleased to present the efficacy and safety findings from the ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection at this year's 2021 AAN Virtual Meeting, specifically, the median duration of effect of up to 24 weeks, as determined by time to loss of 80% peak treatment benefit, suggested that DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually, while being generally safe and well tolerated," said Roman Rubio, Senior Vice President of Clinical Development at Revance. "The findings being presented are part of a growing body of clinical evidence that supports DaxibotulinumtoxinA for Injection's differentiated performance profile and underscores the potential of our therapeutics pipeline for the treatment of muscle movement and pain disorders for patients who suffer from these debilitating conditions."

    The abstracts are available online via the AAN website at www.aan.com.

    ePoster Presentation:

    • Title: A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia

      Authors and Affiliations: Joseph Jankovic, Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX; Cynthia Comella, Rush University Medical Center, Chicago, IL; Robert A. Hauser, Director of the University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL; Atul T. Patel, Kansas City Bone & Joint Clinic, Overland Park, KS; Todd M. Gross, Roman G. Rubio, Domenico Vitarella, Revance Therapeutics, Newark, CA

    ASPEN Phase 3 Clinical Program in Cervical Dystonia

    In 2017, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for DaxibotulinumtoxinA for Injection to treat cervical dystonia, which provides certain developmental and financial benefits to trial sponsors.

    The company's ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults: 1) ASPEN-1, a randomized, double-blind, placebo-controlled, parallel group trial and 2) ASPEN-OLS, an open-label, long-term safety trial.

    Randomized Trial (ASPEN-1): Patients were randomized to a single treatment of either 125 Unit or 250 Unit dose of DaxibotulinumtoxinA for Injection, or placebo. Post-treatment, patients are followed for a maximum of 36 weeks. The primary efficacy endpoint of the trial was the mean change from baseline in the TWSTRS Total Score at the average of Weeks 4 and 6. Key secondary endpoints include the duration of treatment effect, measurement of treatment response on the Clinical and Patient Global Impression of Change assessments, and adverse events. Further, the trial featured exploratory efficacy assessments including the Cervical Dystonia Impact Profile (CDIP-58), a disease-specific, patient-rated questionnaire that measures quality of life.

    Open-Label Study (ASPEN-OLS): Patients receive up to four sequential treatment cycles of DaxibotulinumtoxinA for Injection over the 52-week observation period. Primary endpoints of the trial are safety and immunogenicity after multiple cycles of treatment with DaxibotulinumtoxinA for Injection. Key secondary endpoints are the change from baseline in TWSTRS Total Score and the duration of treatment effect, as well as overall treatment response based on the Clinical and Patient Global Impression of Change. The ASPEN-OLS trial is fully enrolled with a total of 354 patients at sites located in the United States, Canada, and Europe.

    Additional information about the ASPEN Phase 3 program is available at www.clinicaltrials.gov.

    About Cervical Dystonia

    According to the Dystonia Medical Research Foundation, cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck. The movements may be sustained (tonic), jerky (clonic), or a combination. Cervical dystonia (also referred to as spasmodic torticollis) may be primary (meaning that it is the only apparent neurological disorder, with or without a family history) or may be the result of secondary causes (such as physical trauma).

    First-line treatment for cervical dystonia is usually neuromodulator (botulinum toxin) injections, but additional treatments can include oral medications, surgery, and complementary therapies. Neuromodulators block the communication between the nerve and the muscle, relaxing the muscle, which alleviates abnormal involuntary movements and postures. Current neuromodulator treatments for cervical dystonia have a duration of effect of approximately three months. Cervical dystonia can occur at any age, although most individuals first experience symptoms in middle age. The condition affects a few hundred thousand adults and children in the United States alone. The global market opportunity for cervical dystonia was $390 million in 2020 and is expected to grow to $587 million by 2025.1 According to the Decision Resources Group, the global market for treating cervical dystonia and spasticity muscle movement disorders was approximately $1.0 billion in 2020.1

    About Revance Therapeutics, Inc.

    Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

    "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

    Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

    BOTOX® is a registered trademark of Allergan, Inc.

    Forward-Looking Statements

    Any statements in this press release that are not statements of historical fact, including statements related to development of a biosimilar to BOTOX®; statements about our business strategy, the market for our anticipated products and plans and prospects, and potential benefits of our drug product candidates, including with respect to cervical dystonia and muscle movement and pain disorders, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.

    Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results, timing, costs, and completion of our research and development activities and regulatory approvals, including delays in the approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, clinical trials and other aspects of our business; our ability to manufacture supplies for our product candidates; the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results; the applicability of clinical study results to actual outcomes; our ability to successfully compete with other treatments and therapies; our ability to achieve, and the rate and degree of commercial acceptance and the market, size and growth potential of our drug product candidates, if approved; our ability to successfully commercialize our drug product candidates, if approved, and the timing and cost of commercialization activities; our ability to obtain and maintain regulatory approval of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; our ability to develop sales and marketing capabilities; the status of commercial collaborations; our ability to obtain funding for our operations; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risks Factors" on our Form 10-K filed with the SEC on February 25, 2021. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

    1 December 2020 - Decision Resources Group Therapeutic Botulinum Toxin Market Analysis Global 2021

    View Full Article Hide Full Article
  3. Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Fortune has recognized Revance on its 2021 Best Workplaces in Health Care & Biopharma™ list.

    Revance ranked No. 8 in the biopharma category. Fortune partnered with Great Place to Work® on the ranking, which considered more than 825,000 anonymous employee surveys from companies across the health care and biopharma industry. Companies were evaluated on more than 60 elements of employees' experience on the job, including their trust in leadership and workplace culture.

    "We believe that our people are our greatest asset and this recognition underscores our efforts in creating a high-performing culture and work environment…

    Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Fortune has recognized Revance on its 2021 Best Workplaces in Health Care & Biopharma™ list.

    Revance ranked No. 8 in the biopharma category. Fortune partnered with Great Place to Work® on the ranking, which considered more than 825,000 anonymous employee surveys from companies across the health care and biopharma industry. Companies were evaluated on more than 60 elements of employees' experience on the job, including their trust in leadership and workplace culture.

    "We believe that our people are our greatest asset and this recognition underscores our efforts in creating a high-performing culture and work environment that is diverse, inclusive, rewarding and empowering," said Mark Foley, President and Chief Executive Officer of Revance. "We're especially proud to share this recognition with our employees following a year where we have both doubled in size and adapted to a remote work environment given the challenges resulting from the COVID-19 pandemic. I would like to thank all of our employees for their perseverance and commitment to maintaining our positive workplace culture during these trying times while successfully delivering on our corporate objectives."

    "Revance has a strong, dynamic culture that we continue to build upon as we grow our business," said Justin Ford, Senior Vice President, Human Resources and Head of People at Revance. "We believe that the beauty of the world lies in the diversity of its people, and it is this mindset that pushes our culture to be the foundation of our growth and success. Advancing employee engagement, promoting open and honest feedback, hiring great talent, creating an inclusive environment where people can grow and develop and supporting the communities where our people live and work, will continue to anchor our cultural initiatives."

    Revance has been certified by Great Place to Work® for three consecutive years and this is the first year the company was included in the Fortune 2021 Best Workplaces in Health Care and Biopharma™ list.

    The Fortune 2021 Best Workplaces in Health Care and Biopharma™ list is published here: https://www.greatplacetowork.com/best-workplaces/health-care/2021?category=biopharma.

    For more information on Revance's culture, please visit: https://www.revance.com/careers/culture/.

    About the Fortune Best Workplaces in Health Care and Biopharma:

    To determine the Fortune 2021 Best Workplaces in Health Care and Biopharma™ list, Great Place to Work® analyzed anonymous survey feedback representing over 825,000 employees working in the Health Care & Biopharma industries in the United States.

    Employees responded to over 60 survey questions describing the extent to which their organization creates a Great Place to Work For All™. Eighty-five percent of the evaluation is based on what employees say about their experiences of trust and reaching their full human potential as part of their organization, no matter who they are or what they do. Great Place to Work analyzes these experiences relative to each organization's size, workforce make up and what's typical relative to their peers in the industry.

    The remaining 15 percent of the rank is based on an assessment of all employees' daily experiences of innovation, the company's values, and the effectiveness of their leaders, to ensure they're consistently experienced.

    To be considered, companies had to meet the Great Place to Work-Certified standard. To ensure survey results truly represent all employees, Great Place to Work requires that Trust Index© survey results are accurate to a 95% confidence level with a 5% margin of error or better. We review any anomalies in survey responses, news and financial performance to ensure there aren't any extraordinary reasons to believe we couldn't trust a company's survey results. Health Care companies with 10 to 999 people were considered for the small and medium health care category, health care companies with 1,000 employees or more were considered for the large health care category, Biopharma companies with 10 or more employees were considered for the Biopharma category, and those that appear on Fortune's 100 Best Companies to Work For list in their respective industry category are ranked first.

    About Great Place to Work®:

    Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust.

    Great Place to Work helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work For All™.

    About Revance Therapeutics, Inc.

    Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

    "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

    Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

    BOTOX® is a registered trademark of Allergan, Inc.

    View Full Article Hide Full Article
  4. Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company's President and Chief Executive Officer, Mark Foley, will participate in fireside chats at the Cowen 41st Annual Virtual Healthcare Conference on March 3, 2021 and at the Barclays Global Healthcare Conference on March 9, 2021.

    Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

    About Revance Therapeutics, Inc.

    Revance Therapeutics, Inc. is a biotechnology company focused on…

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company's President and Chief Executive Officer, Mark Foley, will participate in fireside chats at the Cowen 41st Annual Virtual Healthcare Conference on March 3, 2021 and at the Barclays Global Healthcare Conference on March 9, 2021.

    Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

    About Revance Therapeutics, Inc.

    Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

    "Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

    Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

    BOTOX® is a registered trademark of Allergan, Inc.

    View Full Article Hide Full Article
  5. Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

    The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness…

    Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.



    The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness about appearance along with the increasing pool of geriatric population is the primary driver that is estimated to catapult the facial injectable market to new heights during the forecast period.



    Moreover, the increasing shift towards minimally invasive procedures and continuous developers in glacial rejuvenation is expected to further augment the growth for the same market. Additionally, the rising awareness regarding the accessibility of various products and procedures, which has stemmed due to the increasing number of players entering the facial injectables space across the globe is forecasted to further add to the surge that the market is expected to witness. Besides, the importance of skincare has gained quite a momentum as exemplified by the fact that 71,800 jobs in 2018 were held by skincare specialists, 47% of which were employed by personal care services in the United States. Additionally, the projected employment in 2028 is estimated at 79,600 [Source: U.S. Bureau of Labor Statistics].



    Further, individualistic value-driven rational has superseded the generic mob mentality of the yesteryears which incentivizes today's consumers to look for products that more oriented to themselves. Further, this interest has also fueled investments in various research studies like that of DREAM (Dysport Real-world Evaluation and Measured satisfaction study) carried out by Galderma after which in May 2020, it announced 95% of patients treated with Dysport achieved high levels of satisfaction with two treatments per year, and 97% of patients believed the result of the treatment looked natural. Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.



    In the same year, HUONS announced that the Korean Ministry of Food and Drug Safety has given it the approval to conduct phase 2 clinical trials for Liztox, its independently developed botulinum toxin (BTX) product that has launched in June 2019, for treating square jaws. Moreover, form the perspective of increasing market reach, in 2020 Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering innovations in neuromodulators for aesthetic and therapeutic indications, announced the signing of a U.S. distribution agreement with TEOXANE SA.



    Under this agreement, Revance is the exclusive commercialization partner of the Swiss company's modern and innovative Resilient Hyaluronic Acid (RHA) technology. TEOXANE's RHA line of fillers include U.S. Food and Drug Administration (FDA)-approved RHA 2, RHA 3, and RHA 4 products, which include lidocaine. The RHA line was designed using a patented crosslinking method that preserves the hyaluronic acid network for correction of moderate-to-severe dynamic facial wrinkles and folds optimizing strength, stretch, and tissue integration. It provides physicians with a broad range of uniquely designed gels for individualized treatment in the face.



    Further due to the upward trend there has been a new development in the aesthetics armlet particularly that pertaining to the facial Injectable market. For instance, in 2020, despite the COVID 19, Galderma announced that "Restylane Kysse" - it's lip filler lip augmentation product, received FDA. Again, Revance Therapeutics, Inc recently announced that the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI), which is its next generation neuro modular product aimed at treating moderate to severe glabellar (frown) lines, has been accepted for review by the U.S. Food and Drug Administration (FDA).



    In 2019 The HydraFacialT Company announced that it has entered into a partnership with Advanced Dermatology and Cosmetic Surgery, the largest dermatology practice in the United States. Furthermore, Allergan plc (NYSE:AGN) announced that it received U.S. Food and Drug Administration (FDA) approval for the use of Juvederm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDET cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21 years. In 2018, Restylane Lyft with Lidocaine, by Q-Med AB was approved by FDA for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds, subcutaneous to subperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21.



    Thus, from the aforesaid, it is evident that the facial injectable market is expected to witness a significant rise during the forecast period, nevertheless, certain adverse effects Viz. allergic reactions, nausea, skin rash, as well as neck and back pain, are expected to deter the growth. Further regularity issues pertaining to botulinum toxin type A, is also expected to pose a hindrance to market growth during the forthcoming years.



    Key Topics Covered:



    1. Introduction

    1.1. Market Definition

    1.2. Market Segmentation



    2. Research Methodology

    2.1. Research Data

    2.2. Assumptions



    3. Executive Summary

    3.1. Research Highlights



    4. Market Dynamics

    4.1. Market Drivers

    4.2. Market Restraints

    4.3. Porters Five Forces Analysis

    4.3.1. Bargaining Power of Suppliers

    4.3.2. Bargaining Power of Buyers

    4.3.3. The threat of New Entrants

    4.3.4. Threat of Substitutes

    4.3.5. Competitive Rivalry in the Industry

    4.4. Industry Value Chain Analysis



    5. Facial Injectable Market Analysis, By Type

    5.1. Introduction

    5.2. Botulinum Toxin

    5.3. Collagen

    5.4. Hyaluronic Acid

    5.5. Particle & Polymer Fillers (PPF)

    5.5.1. Calcium Hydroxyapatite

    5.5.2. Poly-l-Lactic Acid

    5.5.3. Polymethylmethacrylate



    6. Facial Injectable Market Analysis, By Generation

    6.1. Introduction

    6.2. Gen X

    6.3. Boomer

    6.4. Millennials



    7. Facial Injectable Market Analysis, By End-User

    7.1. Introduction

    7.2. Dermatology & Beauty Clinics

    7.3. Hospitals

    7.4. Research Institutes



    8. Facial Injectable Market Analysis, by Geography

    8.1. Introduction

    8.2. North America

    8.2.1. North America Facial Injectable Market Analysis, By Product Type

    8.2.2. North America Facial Injectable Market Analysis, By Generation

    8.2.3. North America Facial Injectable Market Analysis, By End-Users

    8.2.4. By Country

    8.2.4.1. USA

    8.2.4.2. Canada

    8.2.4.3. Mexico

    8.3. South America

    8.3.1. South America Facial Injectable Market Analysis, By Product Type

    8.3.2. South America Facial Injectable Market Analysis, By Generation

    8.3.3. South America Facial Injectable Market Analysis, By End-Users

    8.3.4. By Country

    8.3.4.1. Brazil

    8.3.4.2. Argentina

    8.3.4.3. Others

    8.4. Europe

    8.4.1. Europe Facial Injectable Market Analysis, By Product Type

    8.4.2. Europe Facial Injectable Market Analysis, By Generation

    8.4.3. Europe Facial Injectable Market Analysis, By End-Users

    8.4.4. By Country

    8.4.4.1. Germany

    8.4.4.2. France

    8.4.4.3. United Kingdom

    8.4.4.4. Italy

    8.4.4.5 Others

    8.5. The Middle East and Africa

    8.5.1. Middle East and Africa Facial Injectable Market Analysis, By Product Type

    8.5.2. Middle East and Africa Facial Injectable Market Analysis, By Generation

    8.5.3. Middle East and Africa Facial Injectable Market Analysis, By End-Users

    8.5.4. By Country

    8.5.4.1. Israel

    8.5.4.2. Saudi Arabia

    8.5.4.3. Others

    8.6. Asia Pacific

    8.6.1. Asia Pacific Facial Injectable Market Analysis, By Product Type

    8.6.2. Asia Pacific Facial Injectable Market Analysis, By Generation

    8.6.3. Asia Pacific Facial Injectable Market Analysis, By End-Users

    8.6.4. By Country

    8.6.4.1. China

    8.6.4.2. Japan

    8.6.4.3. South Korea

    8.6.4.4. India

    8.6.4.5. Others



    9. Competitive Environment and Analysis

    9.1. Major Players and Strategy Analysis

    9.2. Emerging Players and Market Lucrativeness

    9.3. Mergers, Acquisitions, Agreements, and Collaborations

    9.4. Vendor Competitiveness Matrix



    10. Company Profiles

    10.1. Allergan (AbbVie Inc)

    10.2. Bausch Health Companies Inc.

    10.3. Bloomage Biotechnology Corporation Limited

    10.4. Galderma

    10.5. Johnson Medical Aesthetics, LLC

    10.6. Merz Pharma

    10.7. Prollenium Medical Technologies

    10.8. Sanofi

    10.9. Sinclair Pharma

    10.10. Suneva Medical



    For more information about this report visit https://www.researchandmarkets.com/r/4fn9up



    CONTACT: ResearchAndMarkets.com
             Laura Wood, Senior Press Manager
             
             For E.S.T Office Hours Call 1-917-300-0470
             For U.S./CAN Toll Free Call 1-800-526-8630
             For GMT Office Hours Call +353-1-416-8900
    

    Primary Logo

    View Full Article Hide Full Article
View All Revance Therapeutics Inc. News